Somerset Researchers Wrap Up National CBD Trial for Parkinson’s Psychosis
Study explores whether cannabis-derived treatment can reduce hallucinations and delusions while improving life for patients and their families
Researchers in Somerset are nearing the end of a UK-wide trial testing a treatment derived from the cannabis plant to help people with Parkinson’s disease who experience psychosis. The study, known as the CAN-PDP trial, aims to see whether the treatment can safely reduce symptoms such as hallucinations and delusions.
Sarah, a consultant geriatrician specialising in Parkinson’s, explained that around 60 per cent of people with Parkinson’s may experience psychotic symptoms during the course of their illness. “These symptoms can range from mild misperceptions to full hallucinations and paranoid beliefs, which can have a huge impact on quality of life,” she said.
Nishi, a research nurse at Musgrove Park Hospital, said the trial provides local patients access to cutting-edge research without having to travel far. “Being part of a national study means our patients can participate right here in Somerset,” she said.
Kimberley, also a research nurse involved in the study, described the effect the symptoms had on patients and their families. “We’ve seen how unsettling hallucinations can be for both the patients and the people they live with,” she said. “It can be frightening, and families sometimes perceive the symptoms differently to the patients themselves.”
The trial has run for 12 weeks at the Musgrove Park Hospital research clinic, where participants were carefully screened before taking part. Patients either received the cannabis-derived treatment or a placebo, while researchers monitored their symptoms and wellbeing.
While the full results are not yet available, early observations suggest that the study could lead to new treatment options. Sarah added: “Any addition to our treatment options is valuable because Parkinson’s symptoms are so individual. Having another tool could be very helpful for patients experiencing these challenging symptoms.”
Kimberley noted that results are expected by March 2026, with letters being sent to participants before Christmas to thank them for their involvement. Patients and families interested in following the study or participating in future trials can find information on the Parkinson’s UK website.
Somerset NHS remains the only site in the South West for the trial, with Cornwall recently joining as a new site. Nishi said the national reach of the study demonstrates the importance of collaboration in improving care for people with Parkinson’s across the region.